Research Topics
| Gahan J PandinaSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Risperidone and cognitive function in children with disruptive behavior disordersGahan J Pandina
Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
Biol Psychiatry 62:226-34. 2007..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed...- Risperidone in the management of disruptive behavior disordersGahan J Pandina
Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, New Jersey, USA
J Child Adolesc Psychopharmacol 16:379-92. 2006..As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters... - Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trialGahan J Pandina
Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
J Autism Dev Disord 37:367-73. 2007..7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism... 
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trialGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
J Affect Disord 118:139-46. 2009....- Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trialGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
Int Clin Psychopharmacol 25:51-9. 2010..In conclusion, PaRTS-D may be useful in symptom presence and severity assessments from the patient's perspective and as an adjunctive to other instruments in major depressive disorder diagnosis and response to treatment... - Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trialsGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
Psychopharmacol Bull 41:68-90. 2008..The Patient-Rated Troubling Symptoms Scale for Anxiety (PaRTS-A) instrument was developed to provide an individualized assessment of patient relevant GAD symptoms... - Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trialGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
Psychopharmacol Bull 40:41-57. 2007.... - Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorderGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08560, USA
J Child Adolesc Psychopharmacol 19:749-56. 2009..The aim of this study was to evaluate cognitive effects from long-term risperidone treatment for disruptive behavior disorders (DBDs) in children and adolescents... - Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescentsMagali Haas
Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
J Child Adolesc Psychopharmacol 18:337-45. 2008..The aim of this study was to determine the long-term safety of risperidone as maintenance therapy in children and adolescents with disruptive behavior disorders (DBDs) and normal intelligence... - Direct health care costs for children with pervasive developmental disorders: 1996-2002Scott C Flanders
Regional Outcomes Research, Ortho McNeil Janssen Scientific Affairs, LLC, 740 Waterford Drive, Grayslake, IL 60030, USA
Adm Policy Ment Health 34:213-20. 2007..1,469 vs. $2,404, respectively, P < 0.0001). Children with PDD incur significantly greater health care costs when compared with children with other chronic pediatric diseases... - Risperidone for treatment-refractory major depressive disorder: a randomized trialRamy A Mahmoud
Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
Ann Intern Med 147:593-602. 2007..Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy)... - A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaGahan J Pandina
Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
J Clin Psychopharmacol 30:235-44. 2010..6% vs 0.0%), and myalgia (1.0% vs 0.0%). The paliperidone palmitate treatment was efficacious and generally tolerated across the dose range (25, 100, or 150 mg eq.) in adult patients with acutely exacerbated schizophrenia... - Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003Scott C Flanders
Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey, USA
J Child Adolesc Psychopharmacol 17:312-27. 2007..The aim of this study was to compare clinical and health services outcomes in pediatric inpatients prescribed an atypical antipsychotic (AA) to those not prescribed an AA at discharge... - Cognitive effects of topiramate in migraine patients aged 12 through 17 yearsGahan J Pandina
Psychiatry, Johnson and Johnson Pharmaceutical Research and Development L L C, Titusville, New Jersey 08560, USA
Pediatr Neurol 42:187-95. 2010..Learning, memory, and executive function were unchanged. The tolerability profile, including cognitive adverse events, appeared to be acceptable... 
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded studyRohan Ganguli
Western Psychiatric Institute and Clinic, O Hara Street, Pittsburgh, PA 15213 2593, USA
BMC Med 6:17. 2008..This paper assesses the short-term results of strategies for the discontinuation of olanzapine when initiating risperidone...- Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophreniaGahan J Pandina
Hum Psychopharmacol 22:326-7; author reply 328. 2007 - A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophreniaGeorges M Gharabawi
J Clin Psychiatry 68:333; author reply 334. 2007 - Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trialsPeter S Jensen
Center for the Advancement of Children s Mental Health, Columbia University, New York State Psychiatric Institute, New York, NY, USA
Eur Child Adolesc Psychiatry 16:104-20. 2007..While there have been studies with duration up to 2 years, no definitive data are available that suggest long-term safety; additional studies are warranted... - No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case seriesJoseph Gonzalez-Heydrich
Children s Hospital Boston, Fegan 8, 300 Longwood Avenue, Boston, MA 02115, USA
J Child Adolesc Psychopharmacol 14:295-310. 2004..The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders...